The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Voyager Therapeutics 14-Day RSI Related Terms
FRA:VT6 vs KROS, CDXS, CAMP: 14-Day RSI Comparison
For the Biotechnology subindustry, Voyager Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (FRA:VT6) has a 14-Day RSI of 53.90 as of Jul. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #838 out of 1419 companies in the Biotechnology industry, placing it in the top 59.1%.
Is Voyager Therapeutics' 14-Day RSI too high?
Voyager Therapeutics' current 14-Day RSI is 53.90. The Biotechnology industry median 14-Day RSI is 48.75. Voyager Therapeutics' value of 53.90 is 10.6% above this industry median. Based on the distribution chart, Voyager Therapeutics ranks #838 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' 14-Day RSI compare to KROS and CDXS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #838 out of 1419 companies for 14-Day RSI. This places Voyager Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 48.75. Voyager Therapeutics' value of 53.90 is 10.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.75, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voyager Therapeutics's current 14-Day RSI of 53.90 is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Voyager Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current 14-Day RSI is 53.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.41, compared to a current price of €3.15 — trading 123.3% above its estimated fair value. The current 14-Day RSI is 53.90 and 10.6% above the Biotechnology industry median of 48.75. Voyager Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current 14-Day RSI is 53.90 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €3.15 is trading 123.3% above its estimated GF Value™ of €1.41.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
14-Day RSI: 53.90
GF Value™: €1.41 vs. price of €3.15 (123.3% above fair value)
Industry Position: 10.6% above the Biotechnology median (#838 of 1419)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
54GF Score
Get the complete analysis for FRA:VT6
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 